Elicio Therapeutics Presents Preclinical Data on AMP TCR-T Combination Therapy in Solid Tumors at the CAR-TCR Annual Summit 2021 Data showed AMP combination with TCR-T cell therapy promotes durable responses against aggressive solid tumors in a mouse model where TCR-T cells alone have no effectAMP combination with TCR-T cell...

Elicio Therapeutics Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002 (AMPLIFY-201) in KRAS-Driven Cancers Study will evaluate the safety and preliminary efficacy of ELI-002, an investigational lymph node-targeted therapeutic vaccine in patients with KRAS-driven tumors, and minimal residual disease...